HD-OPM Archive
Hashtags

#metabolicsyndrome

38 posts

Roy Taylor trial: clearing liver and pancreas fat via 8-week low-calorie diet reversed T2D

Sep 01, 2024 · Louis Nervegna ♥ 24 · 💬 22 ↩ 21 Insulin resistance & diabetes

Louis summarizes Roy Taylor's randomized trial in which an 8-week very low calorie liquid diet cleared fat from the liver and pancreas, restoring insulin sensitivity and beta cell function and putting diabetes into remission. Average weight loss needed was about 15 kg (33 lb), followed by a Mediterranean-style maintenance diet. Some patients had a full curative response with pancreas regeneration seen on imaging.

Nattokinase and PAI-1: how it may work and why PAI-1 matters

Dec 03, 2023 · Gokhan Can ♥ 14 · 💬 16 ↩ 2 Supplements & vitamins

Notes that nattokinase appears to act by inhibiting PAI-1, a marker linking thrombosis, inflammation, metabolic disorder and aging. People who genetically make less PAI-1 live about 7 years longer, and PAI-1 inhibition helped fatty liver and dyslipidemia in preclinical work.

PREDIMED: Mediterranean diet with olive oil or nuts cut major CV events by 30% and 28%

Aug 26, 2025 · Louis Nervegna ♥ 10 · 💬 2 ↩ 7 Mediterranean, DASH, MIND & plant-forward diets

Louis summarizes the PREDIMED randomized trial of about 7,500 people testing the traditional Mediterranean diet for primary prevention. Groups supplemented with extra-virgin olive oil or nuts had a 30% and 28% lower rate of heart attack, stroke or cardiovascular death after 5 years versus an AHA-style control diet. A shared Annals post adds that Mediterranean diet plus calorie reduction and exercise cut diabetes risk by 31% in a large trial.

Semaglutide improved MASH inflammation and fibrosis in the Phase 3 ESSENCE trial

Jun 08, 2025 · Louis Nervegna ♥ 5 · 💬 4 GLP-1 drugs (semaglutide, tirzepatide)

The post argues that liver and pancreas fat drive diabetes, insulin resistance and metabolic syndrome, and that fat leaves the liver early on a diet, which is why GLP-1 drugs work well in fatty liver disease. The shared summary describes the ESSENCE trial of weekly semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2-3 and lists open questions such as cirrhosis and durability.

Fibrates lower triglycerides and may reduce CVD risk in metabolic syndrome

Mar 01, 2024 · Gokhan Can ♥ 5 · 💬 3 LDL, ApoB & lipid panel

Brief overview of fibrates (fenofibrate, gemfibrozil), PPAR-alpha agonists that lower triglycerides, raise HDL and have anti-inflammatory effects. Meta-analyses and real-world data suggest a role for CVD risk reduction in people with metabolic syndrome, especially high triglycerides and low HDL. A 2020 review notes that several RCTs did not show clear benefit overall.

Swapping saturated fat for polyunsaturated seed oils cut CVD events 29% in strict RCTs

Louis states adipose omega-6 is linked to lower mortality in cohorts, and that RCTs meeting strict criteria (no trans fats, supplied food, 2+ years, biomarker-verified adherence, validated events) show a 29% reduction in heart disease events from replacing saturated fat with polyunsaturated fat. He explains why the Minnesota Coronary Experiment, Sydney Heart Study and Rose Corn Oil Trial fail those criteria.